[China coronary secondary prevention study (CCSPS): outcomes from analysis of coronary heart disease patients with diabetes].
OBJECTIVE
To elucidate whether lipid-lowering therapy with Xuezhikang can induce a decrease of cardiac events and an attenuation of total mortality in coronary heart disease (CHD) patients with diabetes.


METHODS
We designed a random, double-blinded, placebo controlled clinical trial in selected 591 patients. All patients were administrated with capsule Xuezhikang (0.6 g, Bid) or placebo in addition to conventional therapy. The mean follow-up period was four years. The primary end-points were nonfatal myocardial infarction and death from CHD.


RESULTS
(1) The incidence of CHD events and that of death from CHD were reduced by 50.8% (P = 0.0008) and by 44.1% (P = 0.0246) in treatment group, respectively; Also, the incidence of nonfatal myocardial infarction was reduced by 63.8% (P = 0.0151). (2) The incidence of stroke, tumor, and PCI/CABG were decreased by 20.2%. (3) The total mortality were lowered by 44.1% in treatment group (P = 0.0097).


CONCLUSIONS
Xuezhikang can effectively reduce the incidence of cardiac events and total mortality in CHD patients with diabetes.
Lu
Zong-liang
ZL
Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
Du
Bao-min
BM
Chen
Zuo
Z
Wu
Yang-feng
YF
Yu
Xue-hai
XH
Zhao
Yu-chen
YC
D000368:Aged; D002681:China; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D003920:Diabetes Mellitus; D004311:Double-Blind Method; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D055502:Secondary Prevention
D004365:Drugs, Chinese Herbal; D000960:Hypolipidemic Agents; C496822:xuezhikang